University of Surrey

Test tubes in the lab Research in the ATI Dance Research

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

Athauda, Dilan, Maclagan, Kate, Budnik, Natalia, Zampedri, Luca, Hibbert, Steve, Skene, Simon S., Chowdhury, Kashfia, Aviles-Olmos, Iciar, Limousin, Patricia and Foltynie, Thomas (2018) What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis Journal of Parkinson's Disease, 8 (2). pp. 247-258.

Full text not available from this repository.

Abstract


Background
Exenatide is a GLP-1 receptor agonist that was recently studied for potential disease-modifying effects in a randomised, placebo-controlled clinical trial in patients with moderate stage Parkinson’s disease, and showed positive effects on the motor severity of the disease which were sustained 12 weeks beyond the period of exenatide exposure. Analysis of pre-defined secondary outcomes revealed no statistically significant differences between patients treated with exenatide in total non-motor symptom burden and overall quality of life measures.
Objective:
The response of individual non-motor symptoms to an intervention may vary and thus this post hoc analysis was conducted to explore the possible effects of exenatide compared to placebo on individual non-motor symptoms.
Results:
Compared to placebo, patients treated with exenatide-once weekly had greater improvements in individual domains assessing mood/depression across all observer-rated outcome measures after 48 weeks including the “mood/apathy” domain of the NMSS, –3.3 points (95% CI –6.2, –0.4), p = 0.026; the “mood” score (Q1.3+Q1.4 of the MDS-UPDRS Part 1), –0.3 points (95%CI –0.6, –0.1), p = 0.034; and a trend in the MADRS total score, –1.7 points (95%CI –3.6, 0.2), p = 0.071. In addition, there was an improvement in the “emotional well-being” domain of the PDQ-39 of 5.7 points ((95%CI –11.3, –0.1), p = 0.047 though these improvements were not sustained 12 weeks after exenatide withdrawal. At 48 weeks these changes were of a magnitude that would be subjectively meaningful to patients and were not associated with changes in motor severity or other factors, suggesting exenatide may exert independent effects on mood dysfunction.
Conclusions:
These exploratory findings will contribute to the design of future trials to confirm the extent of motor and non-motor symptom effects of exenatide in larger cohorts of patients.

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Athauda, Dilan
Maclagan, Kate
Budnik, Natalia
Zampedri, Luca
Hibbert, Steve
Skene, Simon S.s.skene@surrey.ac.uk
Chowdhury, Kashfia
Aviles-Olmos, Iciar
Limousin, Patricia
Foltynie, Thomas
Date : 13 June 2018
DOI : 10.3233/JPD-181329
Copyright Disclaimer : © 2018 – IOS Press and the authors. All rights reserved
Uncontrolled Keywords : Parkinson’s disease; Exenatide; Non-motor symptoms; Clinical trial; GLP-1 agonist
Additional Information : This study was funded by the Michael J. Fox Foundation for Parkinson’s Research and the Cure Parkinson’s Trust and coordinated by University College London’s Comprehensive Clinical Trials Unit.
Depositing User : Diane Maxfield
Date Deposited : 26 Sep 2019 11:58
Last Modified : 26 Sep 2019 11:58
URI: http://epubs.surrey.ac.uk/id/eprint/852809

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800